Cullinan Therapeutics Balance Sheet
NASDAQ: CGEMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cullinan Therapeutics financial position
At the end of fiscal 2025, Cullinan Therapeutics reported total assets of $448.4 million, down 27.9% from a year earlier against total liabilities of $39.6 million. Shareholders' equity stood at $408.7 million, or 91.2% of assets. The company held $88.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 10.25, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Cullinan Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 88.33M | 83.00M | 98.43M | 156.15M | 59.77M | 168.20M |
| Short-Term Investments | 289.56M | 315.97M | 368.63M | 311.14M | 230.69M | 42.01M |
| Total Current Assets | 386.76M | 414.67M | 480.19M | 474.47M | 296.56M | 212.28M |
| Property, Plant & Equipment | 421.00K | 683.00K | 989.00K | 1.17M | 77.00K | 130.00K |
| Long-Term Investments | 58.27M | 204.44M | 0 | 80.88M | 140.40M | 0 |
| Total Assets | 448.37M | 621.82M | 484.18M | 561.12M | 437.19M | 214.71M |
| Accounts Payable | 841.00K | 1.68M | 2.49M | 2.66M | 3.17M | 9.68M |
| Total Current Liabilities | 37.74M | 30.65M | 28.14M | 22.50M | 11.75M | 14.32M |
| Total Liabilities | 39.64M | 31.50M | 30.29M | 26.09M | 11.81M | 14.39M |
| Shareholders' Equity | 408.73M | 590.33M | 453.70M | 535.03M | 424.97M | 199.01M |
| Retained Earnings | -588.12M | -368.24M | -200.86M | -47.70M | -158.91M | -93.34M |
| Net Cash (Debt) | 377.90M | 398.98M | 467.07M | 467.29M | 290.47M | 210.21M |
| Shares Outstanding | 60.24M | 58.51M | 42.90M | 45.80M | 44.29M | 29.83M |
This table shows 6 annual periods of Cullinan Therapeutics's balance sheet, from FY 2025 back to FY 2020, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow CGEM's reporting calendar. What is a balance sheet?